A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.

Ward, S; Morris, E; Bansback, N; Calvert, N; Crellin, A; Forman, D; Larvin, M; Radstone, D and (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health technology assessment (Winchester, England), 5 (24). pp. 1-70. ISSN 1366-5278 DOI: 10.3310/hta5240
Copy
Item Type Article
Keywords Antimetabolites, Antineoplastic/*therapeutic use, Cost-Benefit Analysis, Deoxycytidine/*analogs & derivatives/*therapeutic use, Fluorouracil/therapeutic use, Humans, Pancreatic Neoplasms/*drug therapy, Quality of Life, Antimetabolites, Antineoplastic, therapeutic use, Cost-Benefit Analysis, Deoxycytidine, analogs & derivatives, therapeutic use, Fluorouracil, therapeutic use, Humans, Pancreatic Neoplasms, drug therapy, Quality of Life
Date Deposited 17 Oct 2011 18:08

picture_as_pdf
FullReport-hta5240.pdf
subject
Published Version
Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0
View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads